Kentucky is currently home to 1029 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Flat Dose Vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT04779554
Recruiting
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Peritoneal Carcinomatosis
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-965, Lexington, Kentucky
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Louisville, Kentucky
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/01/2024
Locations: Norton Pulmonary Specialists, Louisville, Kentucky
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Encouraging a Plant Based Diet in an Underserved Urban Population
NCT06090409
Recruiting
The investigator's goal is to promote a plant-based diet amongst the underserved urban population of Louisville with the help of educational aids and the provision of affordable resources.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: University of Louisville Ambulatory Internal Medicine Resident Clinic, Louisville, Kentucky
Conditions: Food Neophobia, Food Preferences, Dietary Habits
Register for Updates
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Norton Cancer Institute, Downtown, Louisville, Kentucky
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Clinical Trial Site, Lexington, Kentucky
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
09/26/2024
Locations: Family Allergy and Asthma Research Institute, Louisville, Kentucky
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
NCT05660382
Recruiting
The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants w... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/23/2024
Locations: Advanced ENT & Allergy, Louisville, Kentucky
Conditions: Otomycosis
Register for Updates
Intermediate Visual Space Perception
NCT05419713
Recruiting
The ability to judge the locations of various objects from oneself during self-motion in the intermediate distance range (\~2-25m) is crucial for successful performance of activities of daily living, such as walking and driving. However, little is known about the mechanisms of visual space perception involved in judging distance, the focus of this project, in the planning and/or execution of self-motion in the natural 3D environment. The theoretical knowledge to be gained from this project will... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
09/23/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Vision
Register for Updates
Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
NCT04677114
Recruiting
This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. The investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. Results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/23/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Drug Use, Opioid-use Disorder
Register for Updates
ArtemiCoffee in Patients With Rising PSA
NCT05478239
Recruiting
Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after localized treatment (radical prostatectomy or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines. It is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/22/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Prostate Cancer
Register for Updates